World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
58
Citations
32965
World Ranking
12875
National Ranking
5478

Michael Kalos publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Michael Kalos sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 145 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Michael Kalos D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Kalos sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 58 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Michael Kalos is affiliated with Next Pillar Consulting in the United States and has contributed to research primarily within the fields of Medicine and Immunology and Microbiology. The scientist's work focuses strongly on Oncology and Immunology, with subfields including Biomedical Engineering, Molecular Biology, and Physiology.

The main topics in Michael Kalos's research include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Biomedical and Engineering Education
  • Angiogenesis and VEGF in Cancer
  • Biomedical Ethics and Regulation

Michael Kalos has published frequently in several venues, with notable contributions to:

  • Cytotherapy
  • Regular and Young Investigator Award Abstracts
  • Cancer Immunology Research
  • PLoS ONE
  • Molecular Cancer Therapeutics

Among recent papers, important publications include:

  • "Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity" (2020) published in Cancer Immunology Research
  • "Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity" (2020) published in Molecular Cancer Therapeutics
  • "Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models" (2022) published in PLoS ONE
  • "Accelerating the development of innovative cellular therapy products for the treatment of cancer" (2020) published in Cytotherapy
  • "Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products" (2024) published in Cytotherapy

Frequent co-authors in Michael Kalos's publications include Ivan Inigo, Ruslan D. Novosiadly, Aleksandra Vuchkovska, Helen Kotanides, and Carmine Carpenito.

Best Publications

  • Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

    David L. Porter;Bruce L. Levine;Michael Kalos;Adam Bagg

  • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

    Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc

  • T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

    Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz

  • Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

    Pablo Tebas;David Stein;Winson W. Tang;Ian Frank

  • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

  • Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

    Gregory L. Beatty;Andrew R. Haas;Marcela V. Maus;Drew A. Torigian

  • NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

    Aaron P Rapoport;Edward A Stadtmauer;Gwendolyn K Binder-Scholl;Olga Goloubeva

  • Use of chimeric antigen receptor-modified t cells to treat cancer

    Carl H. June;Bruce L. Levine;David L. Porter;Michael D. Kalos

  • Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

    Joseph A. Fraietta;Christopher L. Nobles;Morgan A. Sammons;Morgan A. Sammons;Stefan Lundh

  • Monoclonal TCR-redirected tumor cell killing

    Nathaniel Liddy;Giovanna Bossi;Katherine J. Adams;Anna Lissina

  • Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

    John Scholler;Troy L. Brady;Gwendolyn Binder-Scholl;Wei-Ting Hwang

  • Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

    Brian J. Cameron;Andrew B. Gerry;Joseph Dukes;Jane V. Harper

  • Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

    David T. Teachey;David T. Teachey;Susan R. Rheingold;Susan R. Rheingold;Shannon L. Maude;Shannon L. Maude;Gerhard Zugmaier

  • T cells expressing chimeric antigen receptors can cause anaphylaxis in humans

    Marcela V. Maus;Andrew R. Haas;Gregory L. Beatty;Steven M. Albelda

  • Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

    Michael C. Jensen;Leslie Popplewell;Laurence J. Cooper;David DiGiusto

  • Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

    Marco Ruella;David M. Barrett;Saad S. Kenderian;Olga Shestova

  • Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

    Michael Kalos;Carl H. June

  • Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

    Saar Gill;Sarah K. Tasian;Marco Ruella;Olga Shestova

  • RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma

    David L. DiGiusto;Amrita Krishnan;Lijing Li;Haitang Li

  • USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT MALIGNANCIES

    June Carl H;Porter David L;Kalos Michael D;Milone Michael C

Frequent Co-Authors

Carl H. June
Carl H. June University of Pennsylvania
Bruce L. Levine
Bruce L. Levine University of Pennsylvania
David L. Porter
David L. Porter University of Pennsylvania
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Bent K. Jakobsen
Bent K. Jakobsen Continuum Life Sciences
Michael C. Milone
Michael C. Milone University of Pennsylvania
Simon F. Lacey
Simon F. Lacey University of Pennsylvania
David M. Barrett
David M. Barrett Children's Hospital of Philadelphia
Edward A. Stadtmauer
Edward A. Stadtmauer University of Pennsylvania
David T. Teachey
David T. Teachey Children's Hospital of Philadelphia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in Biology or Biochemistry opens doors to a wide range of allied health careers. Many students are choosing flexible, accredited online programs to build specialized skills or begin new career journeys.

If you’re interested in medical imaging, the best online radiology tech programs offer affordable options to train as a radiologic technologist. For those passionate about nutrition science, dietitian masters programs can lead to advanced credentials and greater opportunities in healthcare settings.

Entry-level healthcare roles are also in high demand. You might consider online medical assisting classes, many of which offer financial aid. For current medical assistants aiming to further their careers, a cma to lpn bridge program online could be the next step, providing a path toward becoming a licensed practical nurse.

Each of these online pathways is designed to fit a variety of interests within health and life sciences, making it easier than ever to align your biology or biochemistry background with meaningful career options.

Best Scientists Citing Michael Kalos

Trending Scientists

Recently Published Articles